Baccala Angelo, Sercia Linda, Li Jianbo, Heston Warren, Zhou Ming
Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Urology. 2007 Aug;70(2):385-90. doi: 10.1016/j.urology.2007.03.025.
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer cells. Recently, PSMA has been found in the neovasculature in association with other solid malignant tumors, including clear cell renal carcinoma (RCC). We studied the expression of PSMA in different primary renal tumors.
A tissue microarray was constructed from 60 normal kidney, 21 clear cell RCC (CCRCC), 20 papillary RCC (PRCC), 16 chromophobe RCC, 19 oncocytoma, 14 transitional cell carcinoma, and 19 angiomyolipoma (AML) specimens. This tissue microarray was then immunostained for a vascular endothelial marker CD34 and PSMA. PSMA expression in CD34-positive tumor-associated neovasculature was scored according to the staining intensity and the percentage of vessels. Only diffuse strong or weak, or focal strong PSMA staining was graded as positive.
PSMA was expressed in the proximal tubules of the normal kidney and in the tumor-associated vasculature in the renal tumors. Positive PSMA staining was detected in 76.2% of CCRCC, 31.2% of chromophobe RCC, 52.6% of oncocytoma, 21.4% of transitional cell carcinoma, and 0% of PRCC and AML specimens. Its expression was greater in CCRCC than PRCC, chromophobe RCC, transitional cell carcinoma, and AML (P <0.001), but was not significantly different from the expression in oncocytoma (P = 0.79). PSMA expression did not correlate with the pathologic stage in CCRCC.
PSMA is differentially expressed in the tumor-associated neovasculature in different renal tumors. It is most commonly detected in CCRCC and rarely detectable in PRCC and AML. This finding suggests that antibodies against PSMA may potentially be used as a diagnostic marker and therapeutic target for renal neoplasms.
前列腺特异性膜抗原（PSMA）在前列腺癌细胞中高表达。最近，在包括透明细胞肾细胞癌（RCC）在内的其他实体恶性肿瘤的新生血管中发现了PSMA。我们研究了PSMA在不同原发性肾肿瘤中的表达。
用60例正常肾、21例透明细胞RCC（CCRCC）、20例乳头状RCC（PRCC）、16例嫌色细胞RCC、19例嗜酸细胞瘤、14例移行细胞癌和19例血管平滑肌脂肪瘤（AML）标本构建组织芯片。然后对该组织芯片进行血管内皮标志物CD34和PSMA的免疫染色。根据染色强度和血管百分比对CD34阳性肿瘤相关新生血管中的PSMA表达进行评分。仅弥漫性强或弱、或局灶性强PSMA染色评为阳性。
PSMA在正常肾近端小管及肾肿瘤的肿瘤相关血管中表达。在76.2%的CCRCC、31.2%的嫌色细胞RCC、52.6%的嗜酸细胞瘤、21.4%的移行细胞癌以及0%的PRCC和AML标本中检测到PSMA阳性染色。其在CCRCC中的表达高于PRCC、嫌色细胞RCC、移行细胞癌和AML（P<0.001），但与嗜酸细胞瘤中的表达无显著差异（P=0.79）。PSMA表达与CCRCC的病理分期无关。
PSMA在不同肾肿瘤的肿瘤相关新生血管中差异表达。它最常见于CCRCC，在PRCC和AML中很少能检测到。这一发现表明，抗PSMA抗体可能潜在地用作肾肿瘤的诊断标志物和治疗靶点。
